MG-262

• Description :

  MG-262 (Z-Leu-Leu-LeuB (OH) 2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS) . MG-262 can be used for anti-cancer study[1][2][3][4][5].

• Product Name Alternative :

  Z-Leu-Leu-LeuB (OH) 2; ZL3B

• UNSPSC :

  12352005

• Target :

  Apoptosis; Proteasome; Reactive Oxygen Species (ROS) ; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/mg-262.html

• Purity :

  95.0

• Solubility :

  DMSO : 5 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@H](B(O)O)CC(C)C)[C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC1=CC=CC=C1)=O)=O

• Molecular Formula :

  C25H42BN3O6

• Molecular Weight :

  491.43

• References & Citations :

  [1]Mezquita J, et al. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem. 2003 Aug 15;89 (6) :1138-47. |[2]Wu HM, et al. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett. 2002 Aug 28;526 (1-3) :101-5. |[3]Huang H, et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011 Feb 28;301 (2) :221-8.|[4]Kumarapeli AR, et al A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 2005 Dec;19 (14) :2051-3.|[5]Lindsten K, et al. A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol. 2003 Aug;21 (8) :897-902.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [179324-22-2]